Insights & Updates
in Treatment and Prevention of
C. difficile Infection
in Treatment and Prevention of
C. difficile Infection
Clostridium difficile infection (CDI) is associated with significant morbidity and mortality. Further, recurrence of CDI is common after an initial episode. Although a number of therapies with varying mechanisms of action, are available to treat CDI and prevent recurrence, the management of CDI is complex and challenging. Clinicians require up-to-date knowledge of evidence-based treatment of initial and recurrent CDI to improve clinical outcomes.
Supported by an educational grant from Merck & Company.
Professor of Medicine, Clinical and Translational Science
Co-Director, IBD Center – Translational Research
Director, Nutrition Support Service
Division of Gastroenterology, Hepatology, and Nutrition
University of Pittsburgh
UPMC Presbyterian Hospital
Pittsburgh, PA
Gastroenterology Center of Connecticut
Clinical Instructor of Medicine
Yale University School of Medicine
Hamden, CT
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Portland, OR
Assistant Professor of Medicine
Division of Infectious Diseases
Medical University of South Carolina
Charleston, SC
Associate Professor
Department of Medicine, Infectious Diseases
University of Virginia
Charlottesville, VA
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
